source
- FDA schedules advisory committee meetings for rejected Replimune melanoma drug and Capricor DMD cell therapyThe FDA announced that it will hold two advisory committee meetings this week to revisit investigational therapies that were previously turned down. One meeting will consider Capricor Therapeutics'…
- Roche says its late-stage pipeline is full, sees growth through 2030Roche's CEO Thomas Schinecker told analysts that the company has 19 investigational medicines that could launch by 2030, indicating a robust late-stage pipeline. He added that the depth of the pip…